Gilead Sciences
GILD
1,721 hedge funds and large institutions have $87.4B invested in Gilead Sciences in 2024 Q3 according to their latest regulatory filings, with 171 funds opening new positions, 630 increasing their positions, 698 reducing their positions, and 115 closing their positions.
49% more first-time investments, than exits
New positions opened: 171 | Existing positions closed: 115
36% more funds holding in top 10
Funds holding in top 10: 14 → 19 (+5)
23% more capital invested
Capital invested by funds: $71.3B → $87.4B (+$16.2B)
2% more funds holding
Funds holding: 1,681 → 1,721 (+40)
3% more call options, than puts
Call options by funds: $958M | Put options by funds: $928M
0.44% more ownership
Funds ownership: 83.31% → 83.75% (+0.44%)
10% less repeat investments, than reductions
Existing positions increased: 630 | Existing positions reduced: 698
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.12B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$890M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$362M |
| 4 |
Amundi
Paris,
France
|
+$181M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$137M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$542M |
| 2 |
Two Sigma Advisers
New York
|
-$288M |
| 3 |
Two Sigma Investments
New York
|
-$201M |
| 4 |
D.E. Shaw & Co
New York
|
-$198M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$163M |
GILD Hedge Fund Activity: Q3 2024 in Review
1,721 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2024, worth a combined $87.4B — up 23% from $71.3B a quarter earlier.
Buyers outnumbered sellers: 171 funds opened new GILD positions and 115 closed out — a net gain of 56 holders — while 630 added to existing stakes and 698 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.12B. The largest seller was Pacer Advisors, cutting an estimated $542M.
- 1,721 institutional investors held Gilead Sciences (GILD) as of Q3 2024, up from 1,681 in Q2 2024.
- Funds reported $87.4B of Gilead Sciences stock for Q3 2024, up 23% quarter-over-quarter.
- 171 funds opened new Gilead Sciences positions in Q3 2024 and 115 closed out, a net change of +56 holders.
- The largest Gilead Sciences buyer in Q3 2024 was Fidelity Investments, an estimated $1.12B added.
- The largest Gilead Sciences seller in Q3 2024 was Pacer Advisors, an estimated $542M sold.
Based on aggregated 13F filings for Q3 2024.